PHARM

PHARM (Pharmaceutical Manufacturing in Microgravity) is a UK Space Agency study programme that commissions regulatory-compliant mission design for in-orbit pharmaceutical manufacturing. The agency awarded BioOrbit a £250,000 PHARM contract to develop the mission architecture, safety case and regulatory pathway for a commercial in-orbit drug crystallisation mission, ahead of the 5 March 2026 joint publication by the UK Space Agency, MHRA, Regulatory Innovation Office and CAA that established the UK's framework for approving space-manufactured drugs .

The PHARM study structure exemplifies the UK Space Agency's function as a demand-creation body: rather than funding technology development directly, the contract funds the regulatory and mission-design work that private capital cannot finance alone. The output — a validated mission architecture with a clear regulatory pathway to market — lowers the diligence burden for private investors who subsequently fund the commercial mission. BioOrbit's £9.8m seed round in April 2026, co-led by LocalGlobe and Breega, followed the PHARM study contract; the sequencing is not coincidental.

As a programme category, PHARM sits alongside UK Space Agency contracts for space surveillance (which also produced Spaceflux's NSOC clean sweep ) as instruments where government study contracts function as pre-commercial validation, compressing the risk curve that private capital would otherwise need to price. The PHARM contract's value (£250,000) is modest relative to BioOrbit's seed round; the disproportionate leverage reflects the document rather than the cheque.